IgA血管炎的免疫机制和治疗现状及展望  

Current status and prospects of the immune pathogenesis and treatment of IgA vasculitis

作　　者：杨思睿[1] 刘德滢 王晶华[1] 刘金香[1] 刘聪聪[1] 

机构地区：[1]吉林大学第一医院儿童风湿免疫过敏科,长春130021

出　　处：《中华实用儿科临床杂志》2016年第9期641-645,共5页Chinese Journal of Applied Clinical Pediatrics

摘　　要：IgA血管炎（IgAV）是以小血管为主要病变的系统性血管炎，以非血小板减少性紫癜、关节痛、腹痛及肾炎为主要临床表现，病因及发病机制尚待进一步深入了解。多数患儿病程具有自限性，重症或迁延病例的治疗方案尚待进一步完善，对关键药物的使用尚缺乏可靠的循证依据。期待更多严谨的临床试验，以建立更加科学完整的疾病评价和预判体系，以确立更科学合理的个体化治疗方案。IgA vasculitis （IgAV） is a common systemic small - sized vessel vasculitis. It＇s characterized by non - thrombocytopenic palpable purpura, arthralgia/arthritis, bowel angina, and nephritis, but some details of etiology and pathogenesis is not very clear. The disease course is usually benign and self - limited, however, it is necessary to discuss the therapy of severe or chronic cases, especially there is not enough evidence - based basis for using key drugs to IgAV. Excellent clinical trails is expected to establish scientific system of prediction and evaluation of disease course, which will be helpful to individualize treatment of IgAV.

关 键 词：IgA血管炎 发病机制 治疗 糖皮质激素 

分 类 号：R725.5[医药卫生—儿科]